Gynaecologic Oncology
July 2015
This bulletin covers aspects of gynaecological cancers and should be of interest to multidisciplinary
teams working in this area.
Sections can include:
 Combined Modality Therapies
 Drug Therapy
 Pathology, Staging, Polymorphisms & Biomarkers
 Prognosis, Survival & Risk Factors
 Radiotherapy & Imaging
 Supportive Care & Symptom Management
 Surgery
Many of the following articles are available online via the NHS Scotland Knowledge Network.
Please use the links where provided and your ATHENS password. A complete list of
available online journals and registration for ATHENS can be found at
www.knowledge.scot.nhs.uk/
If the article you require is not available via the NHS Scotland Knowledge Network and you
would like to request a print copy, please submit your request online at
www.quest.scot.nhs.uk
This bulletin contains a selection of material gathered from a search of the evidence base, and is
not intended to be comprehensive. Professional judgment should be exercised when appraising
the material. The Library takes no responsibility for the wording, content and accuracy of the
information supplied, which has been extracted in good faith from reputable sources. NHSGGC is
not responsible for the content of external internet sites.
Compiled by:
Kirsty Coltart
Subject Librarian
Beatson West of Scotland Cancer Centre
0141 301 7285, kirsty.coltart@ggc.scot.nhs.uk
1
Gynaecologic Oncology, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
General
Artioli G, Wabersich J, Ludwig K, et al. (2015). Rare uterine cancer:
carcinosarcomas. Review from histology to treatment. Critical Reviews in
Oncology-Hematology 94,1:98-104.
Fung-Kee-Fung M, Kennedy EB, Biagi J, et al. (2015). An organizational guideline
for gynecologic oncology services. International Journal of Gynecological Cancer
25,4:551-558.
Hunn J, Tenney ME, Tergas AI, et al. (2015). Patterns and utility of routine
surveillance in high grade endometrial cancer. Gynecologic oncology 137,3:485489.
Katsumata, N. (2015). Dose-dense approaches to ovarian cancer treatment.
Current Treatment Options in Oncology 16,5:21.
Rimel BJ, Burke WM, Higgins RV, et al. (2015). Improving quality and decreasing
cost in gynecologic oncology care. Society of gynecologic oncology
recommendations for clinical practice. Gynecologic oncology 137,2:280-284.
Combined Modality Therapies
Bie Y, Zhang Z and Wang X. (2015). Adjuvant chemo-radiotherapy in the
"sandwich" method for high risk endometrial cancer-a review of literature. BMC
Women's Health 15,50.
Kokka F, Bryant A, Brockbank E, et al. (2015). Hysterectomy with radiotherapy or
chemotherapy or both for women with locally advanced cervical cancer.
Cochrane Database of Systematic Reviews 4,010260.
Sardain H, Lavoue V, Redpath M, et al. (2015). Curative pelvic exenteration for
recurrent cervical carcinoma in the era of concurrent chemotherapy and
radiation therapy. A systematic review. European Journal of Surgical Oncology
41,8:975-985.
Sun W, Wang T, Shi F, et al. (2015). Randomized phase III trial of radiotherapy or
chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical
cancer patients after radical hysterectomy. BMC Cancer 15,353.
van Driel WJ, Lok CA, Verwaal V, et al. (2015). The role of hyperthermic
intraperitoneal intraoperative chemotherapy in ovarian cancer. Current Treatment
Options in Oncology 16,4:14.
Wang CC, Chou HH, Yang LY, et al. (2015). A randomized trial comparing
concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus
gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic
Oncology Group study. Gynecologic oncology 137,3:462-467.
Wang X, Shen Y, Zhao Y, et al. (2015). Adjuvant intensity-modulated radiotherapy
2
Gynaecologic Oncology, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
(IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with
high risk factors: A phase II trial. European Journal of Surgical Oncology 41,8:10821088.
Drug & Targeted Therapy
Chen BL, Li J, Chen YY, et al. (2015). A novel external catheter fixation method for
chemotherapy using inferior epigastric arterial catheterization for cervical
cancer. International journal of nursing practice 21,Suppl 2:150-156.
Coleman RL, Sill MW, Bell-McGuinn K, et al. (2015). A phase II evaluation of the
potent, highly selective PARP inhibitor veliparib in the treatment of persistent or
recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in
patients who carry a germline BRCA1 or BRCA2 mutation - An NRG
Oncology/Gynecologic Oncology Group study. Gynecologic oncology 137,3:386391.
Coleman RL, Sill MW, Thaker PH, et al. (2015). A phase II evaluation of selumetinib
(AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of
recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic
Oncology Group study. Gynecologic oncology 138,1:30-35.
Diaz-Padilla I, Wilson MK, Clarke BA, et al. (2015). A phase II study of single-agent
RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with
recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess
Margaret, Chicago and California phase II consortia. Gynecologic oncology
137,2:216-222.
Hirte H, Kennedy EB, Elit L, et al. (2015). Systemic therapy for recurrent, persistent,
or metastatic cervical cancer: a clinical practice guideline. Current Oncology
22,3:211-219.
Kitagawa R, Katsumata N, Shibata T, et al. (2015). Paclitaxel Plus Carboplatin
Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The
Open-Label Randomized Phase III Trial JCOG0505. Journal of Clinical Oncology
33,19:2129-2135.
Konecny GE, Finkler N, Garcia AA, et al. (2015). Second-line dovitinib (TKI258) in
patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic
endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase
2 study. Lancet Oncology 16,6:686-694.
Liu FW, Cripe J and Tewari KS. (2015). Anti-angiogenesis therapy in gynecologic
malignancies. Oncology (Williston Park) 29,5:350-360.
Mahner S, Prieske K, Grimm D, et al. (2015). Systemic treatment of vulvar cancer.
Expert Review of Anticancer Therapy 15,6:629-637.
Marchetti C, Gasparri ML, Ruscito I, et al. (2015). Advances in anti-angiogenic
agents for ovarian cancer treatment: The role of trebananib (AMG 386). Critical
Reviews in Oncology-Hematology 94,3:302-310.
3
Gynaecologic Oncology, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
McMeekin S, Dizon D, Barter J, et al. (2015). Phase III randomized trial of secondline ixabepilone versus paclitaxel or doxorubicin in women with advanced
endometrial cancer. Gynecologic oncology 138,1:18-23.
Pautier P, Floquet A, Chevreau C, et al. (2015). Trabectedin in combination with
doxorubicin for first-line treatment of advanced uterine or soft-tissue
leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet
Oncology 16,4:457-464.
Pignata S, Lorusso D, Scambia G, et al. (2015). Pazopanib plus weekly paclitaxel
versus weekly paclitaxel alone for platinum-resistant or platinum-refractory
advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Lancet Oncology 16,5:561-568.
Rettenmaier MA, Mendivil AA, Abaid LN, et al. (2015). The feasibility of
administering varying high-dose consolidation hyperthermic intraperitoneal
chemotherapy with carboplatin in the treatment of ovarian carcinoma. Archives of
Gynecology & Obstetrics 291,6:1381-1386.
Sehouli J, Fotopoulou C, Erol E, et al. (2015). Alopecia as surrogate marker for
chemotherapy response in patients with primary epithelial ovarian cancer: a
metaanalysis of four prospective randomised phase III trials with 5114 patients.
European journal of cancer 51,7:825-832.
Tempfer CB, Winnekendonk G, Solass W, et al. (2015). Pressurized intraperitoneal
aerosol chemotherapy in women with recurrent ovarian cancer: A phase 2 study.
Gynecologic oncology 137,2:223-228.
Pathology, Staging, Polymorphisms & Biomarkers
Bats AS, Frati A, Mathevet P, et al. (2015). Contribution of lymphoscintigraphy to
intraoperative sentinel lymph node detection in early cervical cancer: Analysis of
the prospective multicenter SENTICOL cohort. Gynecologic oncology 137,2:264269.
de Freitas RR, Baiocchi G, Hatschbach SB, et al. (2015). Can a sentinel node
mapping algorithm detect all positive lymph nodes in cervical cancer?. Annals of
Surgical Oncology 22,5:1564-1569.
Elfstrom KM, Arnheim-Dahlstrom L, von Karsa L, et al. (2015). Cervical cancer
screening in Europe: Quality assurance and organisation of programmes.
European journal of cancer 51,8:950-968.
Frati A, Ballester M, Dubernard G, et al. (2015). Contribution of Lymphoscintigraphy
for Sentinel Lymph Node Biopsy in Women with Early Stage Endometrial Cancer:
Results of the SENTI-ENDO Study. Annals of Surgical Oncology 22,6:1980-1986.
Menon U, Ryan A, Kalsi J, et al. (2015). Risk Algorithm Using Serial Biomarker
Measurements Doubles the Number of Screen-Detected Cancers Compared With
a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian
Cancer Screening. Journal of Clinical Oncology 33,18:2062-2071.
4
Gynaecologic Oncology, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Stelloo E, Bosse T, Nout RA, et al. (2015). Refining prognosis and identifying
targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Modern Pathology 28,6:836-844.
Talhouk A, McConechy MK, Leung S, et al. (2015). A clinically applicable molecularbased classification for endometrial cancers. British journal of cancer 113,2:299310.
Prognosis, Survival & Risk Factors
Bristow RE, Chang J, Ziogas A, et al. (2015). Impact of National Cancer Institute
Comprehensive Cancer Centers on ovarian cancer treatment and survival.
Journal of the American College of Surgeons 220,5:940-950.
Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell
K, et al. (2015). Menopausal hormone use and ovarian cancer risk: individual
participant meta-analysis of 52 epidemiological studies. Lancet 385,9980:18351842.
Lum MM, Belnap TW, Frandsen J, et al. (2015). Survival Analysis of Cancer
Patients With FIGO Stage IIIA Endometrial Cancer. American Journal of Clinical
Oncology 38,3:283-288.
Rauh-Hain JA, Hariton E, Clemmer J, et al. (2015). Incidence and effects on
mortality of venous thromboembolism in elderly women with endometrial cancer.
Obstetrics & Gynecology 125,6:1362-1370.
Rose PG, Java J, Whitney CW, et al. (2015). Nomograms Predicting ProgressionFree Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced
Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors
in Patients From NRG Oncology/Gynecologic Oncology Group Randomized
Trials of Chemoradiotherapy. Journal of Clinical Oncology 33,19:2136-2142.
Suidan RS, Zhou Q, Iasonos A, et al. (2015). Prognostic significance of the number
of postoperative intraperitoneal chemotherapy cycles for patients with advanced
epithelial ovarian cancer. International Journal of Gynecological Cancer 25,4:599606.
Radiotherapy & Imaging
Baker W, Pelkofski E, Te Paske J, et al. (2015). Preoperative imaging of uterine
malignancy: A low-value service. Gynecologic oncology 137,2:285-290.
Borley J, Wilhelm-Benartzi C, Yazbek J, et al. (2015). Radiological predictors of
cytoreductive outcomes in patients with advanced ovarian cancer. BJOG: An
International Journal of Obstetrics & Gynaecology 122,6:843-849.
Chitapanarux I, Tharavichitkul E, Nobnop W, et al. (2015). A comparative planning
study of step-and-shoot IMRT versus helical tomotherapy for whole-pelvis
5
Gynaecologic Oncology, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
irradiation in cervical cancer. Journal of radiation research 56,3:539-545.
Dueholm M, Christensen JW, Rydbjerg S, et al. (2015). Two- and three-dimensional
transvaginal ultrasound with power Doppler angiography and gel infusion
sonography for diagnosis of endometrial malignancy. Ultrasound in Obstetrics &
Gynecology 45,6:734-743.
Hymel R, Jones GC and Simone CB 2nd. (2015). Whole pelvic intensity-modulated
radiotherapy for gynecological malignancies: A review of the literature. Critical
Reviews in Oncology-Hematology 94,3:371-379.
Lee KK, Lee JY, Nam JM, et al. (2015). High-dose-rate vs. low-dose-rate
intracavitary brachytherapy for carcinoma of the uterine cervix: Systematic
review and meta-analysis. Brachytherapy 14,4:449-457.
Lin SY, Tsai CS, Chang YC, et al. (2015). The Role of Pretreatment FDG-PET in
Treating Cervical Cancer Patients With Enlarged Pelvic Lymph Node(s) Shown on
MRI: A Phase 3 Randomized Trial With Long-Term Follow-Up. International journal
of radiation oncology, biology, physics 92,3:577-585.
Wiltink LM, Nout RA, Fiocco M, et al. (2015). No Increased Risk of Second Cancer
After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the
Randomized TME, PORTEC-1, and PORTEC-2 Trials. Journal of Clinical Oncology
33,15:1640-1646.
Supportive Care & Symptom Management
Baker J, Janda M, Graves N, et al. (2015). Quality of life after early enteral feeding
versus standard care for proven or suspected advanced epithelial ovarian
cancer: Results from a randomised trial. Gynecologic oncology 137,3:516-522.
Cotton SC, Sharp L, Little J, et al. (2015). A normal colposcopy examination fails to
provide psychological reassurance for women who have had low-grade
abnormal cervical cytology. Cytopathology 26,3:178-187.
Eleje GU, Eke AC, Igberase GO, et al. (2015). Palliative interventions for controlling
vaginal bleeding in advanced cervical cancer. Cochrane Database of Systematic
Reviews 5,011000.
Frederiksen ME, Njor S, Lynge E, et al. (2015). Psychological effects of diagnosis
and treatment of cervical intraepithelial neoplasia: a systematic review. Sexually
transmitted infections 91,4:248-256.
Grimm D, Hasenburg A, Eulenburg C, et al. (2015). Sexual Activity and Function in
Patients With Gynecological Malignancies After Completed Treatment.
International Journal of Gynecological Cancer 25,6:1134-1141.
Hareyama H, Hada K, Goto K, et al. (2015). Prevalence, classification, and risk
factors for postoperative lower extremity lymphedema in women with
gynecologic malignancies: a retrospective study. International Journal of
Gynecological Cancer 25,4:751-757.
6
Gynaecologic Oncology, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Mitra D, Nout R, Catalano PJ, et al. (2015). Rectal bleeding after radiation therapy
for endometrial cancer. Radiotherapy & Oncology 115,2:240-245.
Mizrahi D, Broderick C, Friedlander M, et al. (2015). An Exercise Intervention During
Chemotherapy for Women With Recurrent Ovarian Cancer: A Feasibility Study.
International Journal of Gynecological Cancer 25,6:985-992.
Mizrahi D, Naumann F, Broderick C, et al. (2015). Quantifying physical activity and
the associated barriers for women with ovarian cancer. International Journal of
Gynecological Cancer 25,4:577-583.
Thygesen MK, Nicolaisen A and Mogensen O. (2015). Video-, Audio-, and ComputerMediated Education of Patients and Relatives in Gynecologic Cancer Care: A
Systematic Review. Cancer nursing 38,4:E42-52.
Surgery
Iavazzo C and Gkegkes ID. (2015). Port-site metastases in patients with
gynecological cancer after robot-assisted operations. Archives of Gynecology &
Obstetrics 292,2:263-269.
Roh JW, Lee DO, Suh DH, et al. (2015). Efficacy and oncologic safety of nervesparing radical hysterectomy for cervical cancer: a randomized controlled trial.
Journal of Gynecologic Oncology 26,2:90-99.
Seror J, Bats AS, Bensaid C, et al. (2015). Risk of port-site metastases in pelvic
cancers after robotic surgery. European Journal of Surgical Oncology 41,4:599-603.
Swenson CW, Berger MB, Kamdar NS, et al. (2015). Risk factors for venous
thromboembolism after hysterectomy. Obstetrics & Gynecology 125,5:1139-1144.
Vair B, Altman AD and Nelson G. (2015). Time to surgery and the risk of cancer
progression in patients with gynaecologic cancers of the lower genital tract.
Journal of Obstetrics & Gynaecology Canada: JOGC 37,4:338-344.
Please note that the journal articles you are accessing are subject to the terms and conditions
imposed by the publisher, so there will be a limit on the number of articles an individual may
download or print from a single issue of a journal. You can consult your local NHSGGC library with
any queries.
If you have any questions regarding this or any other library services please contact Library staff –
contact details are at the beginning of the bulletin.
7
Gynaecologic Oncology, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network
Sources used for this bulletin: OVID databases, SIGN, NICE, Healthcare Improvement Scotland
8
Gynaecologic Oncology, July 2015
Kirsty Coltart, Subject Librarian, NHSGGC Library Network